<DOC>
	<DOCNO>NCT02774421</DOCNO>
	<brief_summary>This study plan detect presence trastuzumab mass spectroscopy relapse posterior fossa ependymoma ( PFEPN ) tumor specimen pre-treated single dose intrathecal ( IT ) trastuzumab , well evaluate toxicity intrathecal trastuzumab combination subcutaneous ( subQ ) Granulocyte-macrophage colony-stimulating factor ( GM-CSF ) child relapse PFEPN</brief_summary>
	<brief_title>Pilot Study Effect Trastuzumab GM-CSF Children With Recurrent Ependymoma</brief_title>
	<detailed_description />
	<mesh_term>Ependymoma</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Age ≥ 12 month &lt; 21 year time study enrollment Patients must diagnose relapse previously histologically confirm PFEPN Magnetic resonance ( MR ) image brain ( perform within 14 day enrollment ) must demonstrate evidence diffuse leptomeningeal spread beyond primary relapse site posterior fossa obstruction cerebrospinal fluid flow ( CSF ) . MR image total spine ( perform within 14 day enrollment ) demonstrate evidence spinal metastatic disease . Patients must clinical indication standard care surgical resection relapse PFEPN tumor enrollment Stratum 1 Patients must meet one follow performance score : Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 , 1 , 2 ; Karnofsky score ≥ 50 patient &gt; 16 year age ; Lansky score ≥ 50 patient ≤ 16 year age . Informed Consent : All patient and/or parent legally authorize representative must sign write informed consent . Assent , appropriate , obtain accord institutional guideline . Organ Function Requirements : Adequate Renal Function define : 1 ) Creatinine clearance radioisotope glomerular filtration rate ( GFR ) ≥70ml/min/1.73 m2 2 ) A serum creatinine base age/gender follow : Maximum Serum Creatinine ( mg/dL ) Age : Male Female 1 month &lt; 6 month 0.4 0.4 6 month &lt; 1 year 0.5 0.5 1 &lt; 2 year 0.6 0.6 2 &lt; 6 year 0.8 0.8 6 &lt; 10 year 1 1 10 &lt; 13 year 1.2 1.2 13 &lt; 16 year 1.5 1.4 ≥ 16 year 1.7 1.4 Adequate Liver Function define : 1 . Total bilirubin ≤1.5 x upper limit normal ( ULN ) age , 2 . Serum glutamic oxaloacetic transaminase ( SGOT ) ( AST ) serum glutamate pyruvate transaminase ( SGPT ) ( ALT ) &lt; 3 x upper limit normal ( ULN ) age Adequate Bone Marrow Function define : 1 . Peripheral absolute neutrophil count ( ANC ) ≥1,000/µL 2 . Platelet count ≥100,000/µL ( transfusion independent ) Adequate Cardiac Function define : 1 . Shortening fraction &gt; 28 % echocardiogram 2 . Ejection fraction &gt; 50 % echocardiogram radionuclide study Patients diagnosis : spinal cord ependymoma , myxopapillary ependymoma , subependymoma , ependymoblastoma , supratentorial ependymoma , mixed glioma NOT eligible either Stratum . Patients evidence metastatic disease MRI NOT eligible either Stratum . Patients clinical contraindication lumbar puncture NOT eligible either Stratum . Prior Therapy : Radiation therapy : At least 28 day must elapse ( time start protocol therapy ) since completion focal radiation therapy current recurrence Stratum 2 ; Patients already undergone radiation therapy current recurrence NOT eligible Stratum 1 . Myelosuppressive chemotherapy : At least 21 day must elapse last dose myelosuppressive chemotherapy ; Patients treat chemotherapy time recurrence NOT eligible either Stratum . Monoclonal antibody : At least three ( 3 ) halflives antibody must elapse since last dose monoclonal antibody ( see Appendix I list halflives ) Surgical resection : Must fully heal surgical procedure safe lumbar puncture accord treat neurosurgeon least 14 day elapse since surgical procedure . Patients opinion investigator may able comply safety monitoring requirement study NOT eligible either Stratum . Concomitant Medications Corticosteroids : Patients receive systemic corticosteroid NOT eligible either Stratum . Investigational Drugs : Patients currently receive another investigational drug NOT eligible either Stratum . Anticancer Agents : Patients currently receive anticancer agent NOT eligible either Stratum . Pregnancy , BreastFeeding , Contraception 1 . Pregnant breastfeed woman NOT eligible . Pregnancy test must obtain female postmenarchal . 2 . Women childbearing potential male participant partner childbearing potential must agree : use `` highly effective , '' nonhormonal form contraception ( include abstinence ) , two `` effective '' form nonhormonal contraception patient and/or partner , Contraception must continue duration study treatment least seven ( 7 ) month last dose study treatment . Patients uncontrolled serious infection NOT eligible either Stratum . Patients previously receive solid organ transplantation NOT eligible either Stratum . Patients history : significant cardiac disease , cardiac disease risk factor , uncontrolled arrhythmias NOT eligible either Stratum .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>